摘要
目的观察葛根素联合舒血宁治疗冠心病的临床疗效,并探讨其对血黏度及血浆同型半胱氨酸(Hcy)水平的影响。方法选取2013年10月—2015年10月徐州民政医院收治的冠心病患者120例,采用随机数字表法分为对照组和观察组,每组60例。对照组患者给予常规治疗,观察组患者在常规治疗基础上给予葛根素注射液联合舒血宁注射液;两组患者均连续治疗21 d。比较两组患者临床疗效、血黏度、血浆Hcy水平及不良反应发生情况。结果观察组患者临床疗效优于对照组(u=3.37,P<0.05)。两组患者治疗前全血黏度高切值、全血黏度低切值、血浆黏度及血浆Hcy水平比较,差异均无统计学意义(P>0.05);观察组患者治疗后全血黏度高切值、全血黏度低切值、血浆黏度及血浆Hcy水平均低于对照组(P<0.05)。两组患者治疗期间均未出现严重不良反应。结论葛根素联合舒血宁治疗冠心病的临床疗效确切,能有效降低患者血黏度及血浆Hcy水平,安全性较高。
Objective To observe the clinical effect of puerarin combined with shuxuening on coronary heart disease,to explore the impact on blood viscosity and plasma Hcy level. Methods A total of 120 patients with coronary heart disease were selected in Civil Administration Hospital of Xuzhou from October 2013 to October 2015,and they were divided into control group and observation group according to random number table, each of 60 cases. Patients of control group received conventional treatment,while patients of observation group received puerarin combined with shuxuening based on conventional treatment; both groups continuously treated for 21 days. Clinical effect,blood viscosity and plasma Hcy level before and after treatment, and incidence of adverse reactions were compared between the two groups. Results The clinical effect of observation group was statistically significantly better than that of control group( u = 3. 37,P < 0. 05). Before treatment,no statistically significant differences of high- shear whole blood viscosity,low- shear whole blood viscosity,plasma viscosity or plasma Hcy level was found between the two groups( P > 0. 05); after treatment, high- shear whole blood viscosity, low- shear whole blood viscosity,plasma viscosity and plasma Hcy level of observation group were statistically significant lower than those of control group( P < 0. 05). No one of the two groups occurred any serious adverse reactions during the treatment. Conclusion Puerarin conbined with shuxuening has certain clinical effect in treating coronary heart disease,can effectively reduce blood viscosity and plasma Hcy level,has relatively high safety.
出处
《实用心脑肺血管病杂志》
2016年第5期157-159,共3页
Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease
